Rocket Pharmaceuticals (RCKT) Non-Current Deffered Revenue (2017 - 2018)
Rocket Pharmaceuticals' (RCKT) quarterly Non-Current Deffered Revenue came in at $457000.0 in Q4 2018, up 327.1% year-on-year from $107000.0 in Q4 2017, and up 4.34% quarter-over-quarter from $438000.0 in Q3 2018.
Rocket Pharmaceuticals (RCKT) Non-Current Deffered Revenue (2017 - 2018) Analysis & Trends
Rocket Pharmaceuticals has disclosed Non-Current Deffered Revenue across 2 years of filings, most recently posting $457000.0 for Q4 2018.
- Non-Current Deffered Revenue for Q4 2018 came in at $457000.0, up 327.1% year-over-year; the trailing twelve-month figure through Dec 2018 was $457000.0 (up 327.1% YoY), and the FY2018 annual result was $457000.0, up 327.1% from the prior year.
- Non-Current Deffered Revenue came in at $457000.0 for Q4 2018 at Rocket Pharmaceuticals, up from $438000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $598000.0 in Q1 2018 to a low of $107000.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Rocket Pharmaceuticals | 296.03 Mn | 296.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 457,000.00 |
| Sep 30, 2018 | 438,000.00 |
| Jun 30, 2018 | 510,000.00 |
| Mar 31, 2018 | 598,000.00 |
| Dec 31, 2017 | 107,000.00 |